Industry News
Pharmaceutical Industry News
Havas Media Network’s Holly Dunn…
Havas Media Network’s Holly Dunn on how pharma can build trust, equity, and smarter patient connections in today’s evolving health marketplaces.
After a progression-free survival…
After a progression-free survival win last year raised hopes for the combo's potential in hepatocellular carcinoma, an overall survival miss brings the study to a close.
Akebia Therapeutics has scrapped…
Akebia Therapeutics has scrapped plans for a trial that could have expanded the patient population for its new anemia drug Vafseo, the company said.
Emma Walmsley and her GSK CEO…
Emma Walmsley and her GSK CEO successor, Luke Miels, are safeguarding the British pharma’s 40 billion-pound-sterling sales projection for 2031 on the back of a strong quarter.
In a bid to ensure that the widest…
In a bid to ensure that the widest swath of people with generalized myasthenia gravis (gMG) can benefit from its blockbuster medicine, argenx is heading to the FDA with positive data in a subset of
Eli Lilly has revealed a plan to…
Eli Lilly has revealed a plan to spend $1.2 billion to upgrade its plant in Carolina, Puerto Rico. The investment will add 100 manufacturing jobs and bolster the company’s capacity to produce oral drugs, including
Texas demanda a los fabricantes de Tylenol por supuesto encubrimiento de riesgos de autismo
La demanda sostiene que las empresas ocultaron deliberadamente a los consumidores pruebas sobre la relación del paracetamol con el autismo y el TDAH, lo cual no está demostrado.
Merck on Wednesday touted trial…
Merck on Wednesday touted trial wins for a pair of Welireg combos. But the combination win with Merck's own Keytruda represented more of a definite victory, according to one group of analysts.
Texas Sues Tylenol Makers, Claiming They Hid Autism Risks
The lawsuit follows claims by President Trump that linked use by pregnant women of acetaminophen to autism, a connection that is unproven.
After weighing other options amid…
After weighing other options amid a continued sales struggle, the company will look to take the only approved hemophilia A gene therapy off its plate two years after its launch.
The FDA has issued another…
The FDA has issued another complete response letter to Regeneron over its high-dose Eylea due to unresolved issues at a Novo Nordisk manufacturing plant. The company, however, is making progress in lining up alternate manufacturing
Novartis has started to feel the…
Novartis has started to feel the squeeze from generics to its top-selling drug, heart therapy Entresto. But despite its two biggest brands underperforming, the company still delivered 7% groupwide sales growth.
Adopting an RTU vial setup for…
Adopting an RTU vial setup for aseptic filling process can help optimize operational efficiency, reduce TCO, and comply with regulatory requirements
Pitted against the…
Pitted against the immunosuppressant mycophenolate mofetil, Roche’s CD20-targeting antibody Gazyva helped more kids and young adults with idiopathic nephrotic syndrome achieve sustained remission after one year, according to a topline readout from the Swiss drugmaker’s
Citing insurance claims data,…
Citing insurance claims data, CSL’s leaders said they expect this season's flu vaccination rates in the U.S. to decline by 12% overall and by 14% for people ages 65 and older compared with last year.
The FDA slammed generics maker…
The FDA slammed generics maker Hetero with a Form 483 after an inspection of one of its warehouses in India uncovered flying birds, skittering lizards and roaming cats, among a host of other infractions.
In Lilly’s new awareness campaign,…
In Lilly's new awareness campaign, the NBA legend shares his sleep apnea story and encourages others to discuss their symptoms with a doctor.
CDMO Catalent has unveiled a new…
CDMO Catalent has unveiled a new corporate brand, which keeps the company’s moniker the same while trading in the simple blue-against-white lettering of its previous logo with a pair of intersecting, speech bubble-like boxes bearing
Cigna’s Evernorth division is…
Cigna's Evernorth division is rolling out a rebate-free model for its pharmacy benefit manager, Express Scripts—meaning one of the industry's "Big Three" is moving away from the oft-criticized approach.
Innovent’s Eli Lilly-partnered…
Innovent's Eli Lilly-partnered mazdutide, a GLP-1/glucagon (GCG) dual receptor agonist, displayed broader effects on patients' blood glucose levels and weight loss than Novo's leading GLP-1 semaglutide in a head-to-head trial.